October 1, 2008 - Rapid Time to Disease State Makes Model Highly Valuable to Researchers - Taconic, one of the largest laboratory rodent providers in the world, together with Samaritan Pharmaceuticals, Inc. (OTC BB:SPHC.OB), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, announced the partnering of Samaritan Pharma's Alzheimer's rat model designed to test new, promising drugs for Alzheimer's disease to Taconic Farms. This rat model is now available exclusively through Taconic. Developed by Samaritan Pharmaceuticals, the Samaritan FAB Rat Model induces Alzheimer's disease, the most common form of dementia occurring in the elderly. The model is groundbreaking in that it offers significant advantages over other options previously available for the study of neurodegenerative diseases like Alzheimer's.
Since only an estimated 5% of all Alzheimer's cases are passed on genetically, the use of genetically modified mouse models poses limitations that are avoided by the FAB model. In addition, the new model requires a significantly shorter time to the disease state, only four weeks, as compared to the much lengthier process required to age transgenic mice... Taconic's Press Release -
